Theravance Biopharma, Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Theravance Biopharma, Inc. (TBPH) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $14.79 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-02-28
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $4.12M, a 18.04% decline year-over-year.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $4.14M, a 6.13% increase year-over-year.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $3.47M, a 35.17% decline year-over-year.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $3.05M, a 7.88% decline year-over-year.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $14.79M, a 15.99% decline from fiscal 2016.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $17.60M, a 87.11% increase from fiscal 2015.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $9.41M, a 112.95% increase from fiscal 2014.
- Theravance Biopharma, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $4.42M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $8.26M derived: sum of 2 quarters · filed 2018-02-28 | $11.74M derived: sum of 3 quarters · filed 2018-02-28 | $14.79M 10-K · filed 2018-02-28 |
| 2017-09-30 | $4.14M 10-Q · filed 2017-11-08 | $7.61M derived: sum of 2 quarters · filed 2017-11-08 | $10.66M 10-Q · filed 2017-11-08 | $15.70M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-06-30 | $3.47M 10-Q · filed 2017-08-09 | $6.52M 10-Q · filed 2017-08-09 | $11.56M derived: sum of 3 quarters · filed 2018-02-28 | $15.46M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-03-31 | $3.05M 10-Q · filed 2017-05-10 | $8.08M derived: sum of 2 quarters · filed 2018-02-28 | $11.98M derived: sum of 3 quarters · filed 2018-02-28 | $17.34M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $8.93M derived: sum of 2 quarters · filed 2018-02-28 | $14.29M derived: sum of 3 quarters · filed 2018-02-28 | $17.60M 10-K · filed 2018-02-28 |
| 2016-09-30 | $3.90M 10-Q · filed 2017-11-08 | $9.26M derived: sum of 2 quarters · filed 2017-11-08 | $12.57M 10-Q · filed 2017-11-08 | $16.26M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $5.36M 10-Q · filed 2017-08-09 | $8.67M 10-Q · filed 2017-08-09 | $12.36M derived: sum of 3 quarters · filed 2018-02-28 | $14.67M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $3.31M 10-Q · filed 2017-05-10 | $7.00M derived: sum of 2 quarters · filed 2018-02-28 | $9.31M derived: sum of 3 quarters · filed 2018-02-28 | $11.44M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $6.00M derived: sum of 2 quarters · filed 2018-02-28 | $8.13M derived: sum of 3 quarters · filed 2018-02-28 | $9.41M 10-K · filed 2018-02-28 |
| 2015-09-30 | $2.31M 10-Q · filed 2016-11-09 | $4.44M derived: sum of 2 quarters · filed 2016-11-09 | $5.72M 10-Q · filed 2016-11-09 | $7.03M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $2.12M 10-Q · filed 2016-08-09 | $3.40M 10-Q · filed 2016-08-09 | $4.71M derived: sum of 3 quarters · filed 2017-03-01 | $6.02M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $1.28M 10-Q · filed 2016-05-10 | $2.59M derived: sum of 2 quarters · filed 2017-03-01 | $3.89M derived: sum of 3 quarters · filed 2017-03-01 | $4.75M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $2.61M derived: sum of 2 quarters · filed 2017-03-01 | $3.47M derived: sum of 3 quarters · filed 2017-03-01 | $4.42M 10-K · filed 2017-03-01 |
| 2014-09-30 | $1.30M 10-Q · filed 2015-11-12 | $2.16M derived: sum of 2 quarters · filed 2015-11-12 | $3.11M 10-Q · filed 2015-11-12 | $3.11M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $861.00K 10-Q · filed 2015-08-13 | $1.81M 10-Q · filed 2015-08-13 | $1.81M derived: sum of 3 quarters · filed 2016-03-11 | $1.81M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $945.00K 10-Q · filed 2015-05-13 | $945.00K derived: sum of 2 quarters · filed 2016-03-11 | $945.00K derived: sum of 3 quarters · filed 2016-03-11 | $945.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $0.00 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-12 | $0.00 derived: sum of 2 quarters · filed 2014-11-12 | $0.00 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |